Atezolizumab is effective in patients with platinum‐treated locally advanced or metastatic urothelial carcinoma with all levels of PD‐L1 expression, and in patients with higher PD‐L1 expression on tumor‐infiltrating immune cells, atezolizumab showed a clear therapeutic benefit.14 Here, CD274 is linked to neoplasm.